NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients

BACKGROUND: The mammalian target of rapamycin (mTOR) functions within the PI3K/Akt signaling pathway as a critical modulator of cell survival. On the basis of promising pre-clinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and tem...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Sarkaria, Jann N., Galanis, Evanthia, Wu, Wenting, Peller, Patrick J., Giannini, Caterina, Brown, Paul D., Uhm, Joon H., McGraw, Steven, Jaeckle, Kurt A., Buckner, Jan C.
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3010479/
https://ncbi.nlm.nih.gov/pubmed/20864273
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2010.05.064
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires